Special Issue "Endoglin in Health and Disease"
Deadline for manuscript submissions: 30 June 2021.
Interests: cancer-associated fibroblasts; colorectal cancer; endoglin; tumor microenvironment; angiogenesis; TGFbeta; tumor–stroma interactions
Special Issues and Collections in MDPI journals
Endoglin is a co-receptor for members of the transforming growth factor (TGF)-β family, and is known for its crucial role during developmental- and tumor angiogenesis. Extensive work has shown the important roles endoglin plays in modulating the TGF-β signaling pathway, thereby regulating endothelial cell proliferation, migration, and differentiation. Mutations in the endoglin gene (ENG) have been linked to the autosomal vascular disorder hereditary hemorrhagic telangiectasia type 1 (HHT1), a disease characterized by vessel abnormalities. In cancer, endoglin is extensively studied in relation to tumor angiogenesis. High endoglin levels have been related to poorer prognoses for patients with solid tumors. Consequently, therapies that interfere with the function of endoglin, like soluble endoglin ligand traps and neutralizing antibodies to endoglin, have been developed and (clinically) evaluated. Besides the important role for endoglin in regulating angiogenesis, recent work also shows a more widespread role for endoglin beyond the endothelium. Endoglin expression is also reported on epithelial (cancer) cells, cancer-associated fibroblasts, smooth muscle cells in pathological conditions, and cells of the innate- and adaptive immune system. This Special Issue will bring together the most recent work on endoglin in regulating angiogenesis, but also on its role in non-endothelial cells and the potential of endoglin targeting as a new treatment option in various diseases.
Dr. Lukas J.A.C. Hawinkels
Prof. Marie-José Goumans
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- bone morphogenetic protein
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Endoglin and the hematopoietic system
Title: Endoglin in hepatocellular carcinoma
Title: Endoglin under the Spotlight of Cancer Treatment